| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4212430 | Respiratory Medicine | 2008 | 7 Pages |
SummaryMuch effort has been devoted to the identification of immunologically important factors in tuberculous pleurisy (TBP) and malignant pleurisy (MP) to improve the differential diagnosis of the two major causes of lymphocyte-dominant pleurisy. This study evaluated the immunoreactivity and potential diagnostic utility of both host (cytokines and chemokines) and pathogen (mycobacterial proteins) factors in pleural effusions. Effusion samples were collected from 41 patients with MP caused by lung cancer and from 81 patients with TBP. The concentrations of nine cytokines and chemokines (interleukin (IL)-12 p40, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, IL-6, IL-10, CXCL8/IL-8, CXCL10/IP-10, CCL3/MIP-1α, and CCL4/MIP-1β) and antibody responses (IgG, IgM, and IgA) against five Mycobacterium tuberculosis antigens (early secreted antigenic target (ESAT)-6, 30-kDa, MTB12, 38-kDa, and a heparin-binding hemagglutinin (HBHA)) were determined in pleural fluids using enzyme-linked immunosorbent assays (ELISA). In the logistic regression, IFN-γ (odds ratio, 7.178; 95% confidence interval (CI), 2.258–22.817; p=0.001), IL-12 p40 (odds ratio, 11.037; 95% CI, 3.38–36.037; p<0.001), and IL-6 (odds ratio, 3.295; 95% CI, 1.147–9.463; p=0.027) were found to be statistically significant cytokines predicting tuberculous from malignant effusions. Although IgG responses to all of the M. tuberculosis antigens tested were significantly higher in effusions from TBP (p<0.001) compared with those from MP, the logistic regression showed IgG levels for ESAT-6 and MTB12 to be statistically significant for differentiation of TBP from MP. HBHA showed the highest sensitivity of IgM antibody responses in TBP in comparison with other antigens. These data indicate that selected mycobacterial antigens (ESAT-6 and MTB12) and cytokine markers (IFN-γ, IL-12p40, and IL-6) provide useful information for differentiating tuberculous and malignant effusions in clinical practice.
